Timothy Bailey
New York,NY
Summary
Experienced pharmaceutical research biologist seeking new opportunities
Overview
26
26
years of professional experience
Work History
Senior Principal Scientist-Discovery Technologies
Eli Lilly and Company
New York, NY
06.2020 - Current
- 3D culture with organoids generated from patient samples
- 3D screening assays (384 well) using organoids with a specific genetic fingerprint to look at drug combinations
- Co-culture assays with organoids expressing a fluorescently labeled protein of interest. Test the ability of monospecific and bispecific antibodies to inhibit the ability of Neon Green labeled activated T-cells to invade the organoid. High content imaging readout as well an endpoint biochemical assay
- Sort cells with Sony SH800
- Maintain sorter and automated flow suite
Principal Research Associate-Quantitative Biology
Eli Lilly and Company
New York, NY
06.2016 - 06.2020
- Developed and validated receptor occupancy assays using human whole blood for transfer to CRO
- Developed and executed cell based assays (96 and 384-well) for screening novel antagonists of pathways involved in cancer cell growth
- Conducted whole cell binding and blocking experiments with bispecific and monospecific antibodies
- Conducted multi-color flow experiments with whole blood from treated mice to demonstrate target engagement and characterize T-cell populations after drug treatment
- Provided quantitative flow for oncology projects (receptor density experiments)
- Generated cell lines expressing proteins of interest with fluorescent tags using viral transduction. Use in high content imaging assays
Senior Research Associate-Oncology
Eli Lilly and Company
New York, NY
03.2014 - 06.2016
- ex vivo MOA studies for Latruvo
- Developed and validated biomarker assay for Latruvo
- Isolated PBMC's for specific immune testing
- Conducted multi-color flow experiments to support Oncology projects
- Supervised summer interns
Research Associate-Oncology
Eli Lilly and Company
New York, NY
04.2011 - 03.2014
- Conducted ex vivo MOA preclinical studies for candidate antibodies. Looked at downstream pathways by western blot, flow and ELISA.
- Conducted POC studies for new targets using commercially available reagents
- Developed and validated IHC assay for the RON program
- Prepared BLA reports for Latruvo
- Internalization assays with antibodies of interest
Research Scientist II-Oncology
ImClone Systems a wholly owned subsidiary of Eli Lilly
New York, NY
02.2009 - 04.2011
- Carried out cell based MOA studies for Latruvo and IMC-RON8 for IND filing with the FDA. Wound healing, phospho, internalization and soft agar assays were employed to determine what effects our monoclonal antibodies had in the presence and absence of ligand
- Created study reports for IND filing compliant with FDA standards
- Identified and validated novel ion channel targets involved in cancer metastasis
- Generated cell lines with relevant expression of protein(s) of interest
- Validated binding and blocking ELISAs for antibody screening
Research Biologist
Merck
Rahway, NJ
01.2000 - 02.2009
- Developed and validated automated electrophysiology assays for screening small molecule modulators of ROMK, Nav1.7, Nav1.8, and voltage gated calcium channels
- Pre-clinical assays with candidate molecules to determine off target binding and potential side effects
- Conducted MOA studies of pain therapeutics entering clinical trials
- Cloning and expression of ion channel targets
- Developed and validated FLIPR and VIPR assays for drug screening (96 and 384-well)
- Supervised summer students' research projects
Education
Master of Science - Biological Sciences
State University of New York At Fredonia
Fredonia, NY08.1999
Bachelor of Science - Biological Sciences
St. Bonaventure University
St. Bonaventure, NY06-1997
Skills
- Multi-color flow
- Cell based assay design and validation
- Electrophysiology
- Solid state assays
- Mammalian cell culture; immortalized and primary
- 3D culture and assays
- Stable cell line generation
- HTS
- High content imaging
- Receptor occupancy assays
- Drug screening assays
- Data interpretation
Affiliations
Zhu Y, de Jesus RK, Tang H, Walsh SP, Jiang J, Gu X, Teumelsan N, Shahripour A, Pio B, Ding FX, Ha S, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, et al. Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold. Bioorg Med Chem Lett. 2016 Dec 1;26(23):5695-5702.
Tang H, Zhu Y, Teumelsan N, Walsh SP, Shahripour A, Priest BT, Swensen AM,Felix JP, Brochu RM, Bailey T, et al. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure. ACS Med Chem Lett. 2016 May 12;7(7):697-701.
Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, SwensenAM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T,et al.Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation. ACS Med Chem Lett. 2015 May7;6(7):747-52.
Walsh SP, Shahripour A, Tang H, de Jesus RK, Teumelsan N, Zhu Y, Frie J,Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, et al. Differentiation of ROMKpotency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorg Med Chem Lett. 2016 May 1;26(9):2339-43.
Garcia ML, Priest BT, Alonso-Galicia M, Zhou X, Felix JP, Brochu RM, Bailey T, et al. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. J Pharmacol Exp Ther. 2014Jan;348(1):153-64.
Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM,Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, et al. Discovery of a novel sub-class of ROMK channel inhibitors typifiedby5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5829-32.
Felix JP, Priest BT, Solly K, Bailey T, Brochu RM, Liu CJ, Kohler MG, Kiss L, Alonso-Galicia M, Tang H, Pasternak A, Kaczorowski GJ, Garcia ML. The inwardly rectifying potassium channel Kir1.1: development of functional assays to identify and characterize channel inhibitors. Assay Drug Dev Technol. 2012Oct;10(5):417-31.
Tang H, Walsh SP, Yan Y, de Jesus RK, Shahripour A, Teumelsan N, Zhu Y, Ha S, Owens KA, Thomas-Fowlkes BS, Felix JP, Liu J, Kohler M, Priest BT, Bailey T,Brochu R, Alonso-Galicia M, Kaczorowski GJ, Roy S, Yang L, Mills SG, Garcia ML,Pasternak A. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics. ACS Med Chem Lett. 2012 Mar 28;3(5):367-72.
Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J,Bailey T, Burns C, Brekken RA, Loizos N. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts. Mol Cancer Ther. 2012Nov;11(11):2473-82.
Felix JP, Liu J, Schmalhofer WA, Bailey T, et al. Characterization of Kir1.1channels with the use of a radiolabeled derivative of tertiapin. Biochemistry.2006 Aug 22;45(33):10129-39. Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB,Kaczorowski GJ, Garcia ML, Koltzenburg M, Priest BT. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol. 2008 Nov;74(5):1476-84.
Mitra A, Bailey TD, Auerbach AL. Structural dynamics of the M4 transmembrane segment during acetylcholine receptor gating. Structure. 2004 Oct;12(10):1909-18.
Bailey TD, Chakrapani S, Auerbach A. Gating dynamics of the acetylcholine receptor extracellular domain. J Gen Physiol. 2004 Apr;123(4):341-56.
Chakrapani S, Bailey TD, Auerbach A. The role of loop 5 in acetylcholine receptor channel gating. J Gen Physiol. 2003 Nov;122(5):521-39.
Timeline
Senior Principal Scientist-Discovery Technologies
Eli Lilly and Company
06.2020 - Current
Principal Research Associate-Quantitative Biology
Eli Lilly and Company
06.2016 - 06.2020
Senior Research Associate-Oncology
Eli Lilly and Company
03.2014 - 06.2016
Research Associate-Oncology
Eli Lilly and Company
04.2011 - 03.2014
Research Scientist II-Oncology
ImClone Systems a wholly owned subsidiary of Eli Lilly
02.2009 - 04.2011
Research Biologist
Merck
01.2000 - 02.2009
Master of Science - Biological Sciences
State University of New York At Fredonia
Bachelor of Science - Biological Sciences
St. Bonaventure University
Similar Profiles
COLLEEN SGROICOLLEEN SGROI
Candidate Care Coordinator at Eli Lilly and CompanyCandidate Care Coordinator at Eli Lilly and Company
Andrew MalettaAndrew Maletta
Associate Director - Automation - Device Assembly and Packaging at Eli Lilly and CompanyAssociate Director - Automation - Device Assembly and Packaging at Eli Lilly and Company
Shahenaj SayyadShahenaj Sayyad
Scientific Editor at Eli Lilly And CompanyScientific Editor at Eli Lilly And Company
ROYIA Alhazmi senior therapy area specialistROYIA Alhazmi senior therapy area specialist
Senior Therapy Area Specialist at Eli Lilly and companySenior Therapy Area Specialist at Eli Lilly and company
Shahzeb ArifShahzeb Arif
Vice President, Analytics at Publicis CollectiveVice President, Analytics at Publicis Collective